CARL Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 19.97%, SMA50 14.99%, SMA200 10.0%). The stock’s 14-day RSI is 65.95 (firm momentum), while the ATR of 0.96 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -15.3% below its high and over 36.71% above its low. Average 10-day trading volume of 128.66 thousand shares is below the 3-month average of 170.82 thousand, indicating normal recent market interest.

Carlsmed, Inc. has 27.18 million shares outstanding. The public float is 15.55 million shares, elevated short interest at 13.43% of float. This equals 1.36 million shares. The short ratio is 7.57 days. Institutional investors hold 71.97% of the float. Insiders own 43.73%. Over the past six months, insider transactions show net selling. They sold 197.86 thousand shares across 1 transactions.

Carlsmed, Inc. (NASDAQ:CARL) closed at $13.43 USD, gaining $0.50 (3.87%) from the previous close of $12.93. The stock is currently mid-range between its 52-week high and low $8.50 and $17.19. With a market capitalization of about $365.09 million, Carlsmed, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.77). Key stats such as the average daily volume over the past year has been around 170.83 thousand shares, in line with its 52-week average. Headquartered in Carlsbad, CA, Carlsmed, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Michael Cordonnier, the company employs approximately 127 people and listed since July 23, 2025. Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions.

Wall Street analysts project EPS growth of 19.08% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 9 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $24.00 to $17.00. The high target offers 78.7% upside. The low target suggests 26.58% downside. The mean target is $19.80. This offers 47.43% upside. Carlsmed, Inc. earnings surprise history is a mixed track record. The quarter that ended May 05, 2026, missed forecasts by -25.58%. The prior quarter beat by -25.58%. Over the last six quarters, Apple has recorded several small beats. These include -3.29% in August 28, 2025.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

currently trading near 52-week highs band. Valuation shows Carlsmed, Inc. trading at a premium to the broader market with a P/E of -5.54. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $19.80, suggesting 47.43% upside. Our AI forecast model points to short-term strength (1.56% over two weeks), a medium-term fall (-16.68% over three months), and a longer-term gain (44.01% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Carlsmed, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.56%, with price expected at $13.64 by August 18, 2026, within a range of $12.90 to $14.49 3-Month Outlook: Projected fall of -16.68%, reaching $11.19 by October 30, 2026, with a range of $10.91 to $11.46. 1-Year Outlook: Projected gain of 44.01%, with price at $19.34 by August 04, 2027, within a range of $18.97 to $19.70.

Carlsmed, Inc. trades at a P/E ratio of -5.54, slightly below the S&P 500 average, with a price-to-sales ratio of 6.51 and a price-to-book ratio of 3.93 trading at moderately above to book value. The P/FCF stands at -10.71, also below market averages.